The systemic and resistant nature of metastatic castration-resistant prostate cancers (mCRPC) renders them largely incurable even after intensive multimodal therapy. The proliferation, survival, metastasis, and epithelial-mesenchymal transition (EMT) are four vital events that are deeply linked to carcinogenesis. Hence, it is necessary to find a new combination of several therapies, targeting those vital mechanisms with minimal side effects. Significant research works have shown differential low expression of the metabolic Farnesoid X receptor (FXR) in primary and metastatic prostate cancer...